VX-702

For research use only.

Catalog No.S6005

18 publications

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's VX-702 has been cited by 18 publications

3 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

  •  Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

  • J Invest Dermatol, 2018, 138(6):1380-1390. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell NXjKN|NZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFE2PDNizszN NYDYOohYW0GQR1XS
human NCI-H720 cell M1v1dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;hUGhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMU[4NkDPxE1? NGrXRXpUSU6JRWK=
JVM-2 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGpXVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPFMh|ryP NIjkWo1USU6JRWK=
human NCI-H69 cell M1HTNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHe3W|BKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB7OUSxJO69VQ>? NEfNOnlUSU6JRWK=
human BV-173 cell NVPFeGJxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M33jRmlvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTN6NjFOwG0> MoHyV2FPT0WU
human KU812 cell M2LjXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHIZ2tEUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJ2OEig{txO NGjlPG5USU6JRWK=
human DU-145 cell NH;WUIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVQ2PTRizszN M4D0TnNCVkeHUh?=
KARPAS-45 cell MoC0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1rFV2lvcGmkaYTpc44hd2ZiaIXtZY4hU0GUUFHTMVQ2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNEiyOkDPxE1? M1nuO3NCVkeHUh?=
human AGS cell M4XmRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfKVIpKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVUzPTFizszN MYnTRW5ITVJ?
human MOLT-13 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHGTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTl6MTFOwG0> NVPWOoRpW0GQR1XS
human NCI-H209 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzV6IN88US=> NFTwNGNUSU6JRWK=
human CTV-1 cell M{DXc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXj1WVVuUW6qaXLpeIlwdiCxZjDoeY1idiCFVG[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTh|OEmg{txO M3\U[HNCVkeHUh?=
LU-139 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWfJcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk1OzVizszN Moj3V2FPT0WU
ML-2 cell NGPOcmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyOlYyKM7:TR?= M3r1TXNCVkeHUh?=
human K5 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXPSRpVKUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI6OTdizszN MnrXV2FPT0WU
human SBC-1 cell NX;SVHl3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXnNR5FoUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> M1jYUnNCVkeHUh?=
human COR-L88 cell M1HqO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnLMTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR6IN88US=> MY\TRW5ITVJ?
human KY821 cell NVHVc5dUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF;CPXZKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTZyMzFOwG0> MkT1V2FPT0WU
human HCC2218 cell M{G5RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjQZXB3UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNlE5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52OUeyPEDPxE1? NGj5N3ZUSU6JRWK=
human ECC10 cell M2jyUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3Hy[2lvcGmkaYTpc44hd2ZiaIXtZY4hTUOFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY2Ozh7IN88US=> M4rnZ3NCVkeHUh?=
human EW-3 cell M{\6Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLk[2OlEyKM7:TR?= M1n4eXNCVkeHUh?=
human EW-18 cell M3SwS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlP4TY5pcWKrdHnvckBw\iCqdX3hckBGXy1zODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|Q3PzlizszN M4LxV3NCVkeHUh?=
human UACC-257 cell NHnBZ2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrYSWhvUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMkCzNlYh|ryP NILyUIhUSU6JRWK=
human G-361 cell M1P5Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60PVUyQSEQvF2= MUXTRW5ITVJ?
human HMV-II cell M1jzXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHO[|drUW6qaXLpeIlwdiCxZjDoeY1idiCKTW[tTWkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjd5MUi0JO69VQ>? NX7zPIppW0GQR1XS
human DEL cell M{fFU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3LNcGlvcGmkaYTpc44hd2ZiaIXtZY4hTEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNFcxPCEQvF2= NFjpUnNUSU6JRWK=
human IGROV-1 cell M2\Se2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXrNZ4dHUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi52M{G4PEDPxE1? NIO4[JJUSU6JRWK=
human SK-OV-3 cell MorwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3ERYNGUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MU[5O{DPxE1? MnvQV2FPT0WU
human LAMA-84 cell M332S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnjETY5pcWKrdHnvckBw\iCqdX3hckBNSU2DLUi0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44OTJ6NDFOwG0> NX3r[ZlFW0GQR1XS
human NCI-H510A cell NYX1[4NwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1XWfmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MkWyOkDPxE1? NXPOV21kW0GQR1XS
human CP66-MEL cell MljvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2[yeGlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl|NUW5JO69VQ>? MlTiV2FPT0WU
human HAL-01 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFvQT3dKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjd7MUig{txO M1;RZ3NCVkeHUh?=
human RS4-11 cell  M{\VeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmLyTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlcxPTd|IN88US=> MXTTRW5ITVJ?
human RPMI-8226 cell M{XqNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HhPGlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24NlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56MkO3OkDPxE1? MoGwV2FPT0WU
human NCI-H82 cell NInLWI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGjjTHJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IPFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh7M{C1JO69VQ>? MX7TRW5ITVJ?
human NY cells M4DHUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5{N{[zO{DPxE1? NETqRmZUSU6JRWK=
human MDA-MB-361 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVv6e5BQUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60N|E2QCEQvF2= M2S0cXNCVkeHUh?=
human MOLT-4 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXvneZhnUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>? NYT3V5BmW0GQR1XS
human DU-4475 cell NFn3c2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXraVmp1UW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yNUW2OUDPxE1? MnfJV2FPT0WU
human ESS-1 cell NHHzcWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfJTY5pcWKrdHnvckBw\iCqdX3hckBGW1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlkyPzlizszN MmH4V2FPT0WU
human NCI-H1299 cell M{jVNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTNyM{Og{txO MmTWV2FPT0WU
human COLO-684 cell M{PHe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX;X[m1HUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUixOlUh|ryP M1HaPXNCVkeHUh?=
human MV-4-11 cell NFHGUlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFHHTJlKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjdzMUm5JO69VQ>? NWLoVWF2W0GQR1XS
human D-542MG cell M4\mTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGLI[WhKdmirYnn0bY9vKG:oIHj1cYFvKERvNUSyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN7MkeyJO69VQ>? Mo\jV2FPT0WU
human A4-Fuk cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFzTTGRKdmirYnn0bY9vKG:oIHj1cYFvKEF2LV\1b{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPDN4NkKg{txO M2DZc3NCVkeHUh?=
human HL-60 cell NWfoT4Q6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz61NlIyOiEQvF2= NWWwVoVIW0GQR1XS
human NCI-H526 cell NXzSUFJvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIXSXJFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py53OUiwNUDPxE1? NV7yS|dDW0GQR1XS
human L-363 cell NYjqTpNjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4TVdWlvcGmkaYTpc44hd2ZiaIXtZY4hVC1|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlc6OjV{IN88US=> NXP5S4ZSW0GQR1XS
human A388 cell NX;xUXB{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnn1TY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64NFM5PCEQvF2= NYfkOHF3W0GQR1XS
human MS-1 M1jOOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlLCTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64N|Q3PSEQvF2= NX;vSopbW0GQR1XS
human JAR cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2Dvd2lvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64OFkzOyEQvF2= MWnTRW5ITVJ?
human TI-73 cell NYrzOFdzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnrZTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFYzOiEQvF2= NIPm[pBUSU6JRWK=
human CTB-1 cell MnTSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXSwT5J[UW6qaXLpeIlwdiCxZjDoeY1idiCFVFKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvOTd6MkWg{txO Mn;EV2FPT0WU
human SK-NEP-1 cell M13ab2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\DTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjNyM{ig{txO MonEV2FPT0WU
human HT-29 cell NH;SWldIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEK0d5RKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTFzMTFOwG0> MUfTRW5ITVJ?
human NCI-H1092 cell M2PaZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPONm1KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF2LkOxPEDPxE1? MkjWV2FPT0WU
human KMOE-2 cell NYnVNlJJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGtOV0VvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlYyPzhizszN MnrsV2FPT0WU
human EM-2 cell NX7rcnRnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEm3WZNKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4zQDRzIN88US=> NG\0OJRUSU6JRWK=
human RT-112 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;WTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4{QTh2IN88US=> M4rvfnNCVkeHUh?=
human DB cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHiR5dEUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlg2OTNizszN NH24No9USU6JRWK=
human NCI-H1770 cell NEfYfnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIjFOXpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 MV\TRW5ITVJ?
human CAL-54 cell M3ru[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX;KUmllUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPi55MzFOwG0> MWrTRW5ITVJ?
human NB14 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HxeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG3MlY{QTVizszN NFfCcWRUSU6JRWK=
human RPMI-7951 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn6yTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUe5OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS5zN{izJO69VQ>? MYrTRW5ITVJ?
human T47D cell NFSydJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HiW2lvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlIzPDNizszN MYTTRW5ITVJ?
human A549 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTvUphVUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOjhzMTFOwG0> NE\zPFNUSU6JRWK=
human A2780 cell NUXydoNZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHq0TINKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDJ{NTFOwG0> M{fBTnNCVkeHUh?=
human SK-MEL-24 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnG0TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNlQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Oy5yM{GxJO69VQ>? MWDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A
Smiles NC(=O)N(C1=NC(=C(C=C1)C(N)=O)C2=C(F)C=C(F)C=C2)C3=C(F)C=CC=C3F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID